234080 — JW Life Science Share Price
Last trade - 00:00- KR₩176bn
- KR₩236bn
- KR₩222bn
- 83
- 91
- 83
- 98
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.02 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -25.77% | ||
| Dividend Yield (f) | 4.42% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.87 | ||
| Price to Tang. Book | 1.43 | ||
| Price to Free Cashflow | 4.34 | ||
| Price to Sales | 0.79 | ||
| EV to EBITDA | 4.54 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.63% | ||
| Return on Equity | 24.45% | ||
| Operating Margin | 16.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 183,521.05 | 169,816.95 | 188,931.17 | 206,860.37 | 222,478.1 | 243,500 | 263,400 | 5.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +3.85 | -41.48 | +14.87 | +89.03 | +55.5 | -34.43 | +2.58 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
JW Life Science Co. Ltd. is a Korea-based company primarily engaged in manufacture and distribution of Intravenous (IV) fluid products and infusion solutions. The Company is engaged in manufacture of basic IV fluid including water, electrolytes and glucose; nutrient infusion solution including amino acids, lipids, proteins, vitamins and minerals; and special infusion solution, which is used in special cases. The Company is also engaged in manufacture of total parenteral nutrition (TPN) products and others.
Directors
- Jong Ho Lee CHM (84)
- Gyeong Ha Lee CEO (53)
- Gu Seo Park CEO (60)
- Seong Nam Cha OTH
- Cheol Won Park OTH (72)
- Eun Gyeong Hahm DRC (53)
- Jae Cheol Gwon NED
- Yin Sik Lee NED
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 10th, 1994
- Public Since
- October 27th, 2016
- No. of Shareholders
- 20,046
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 15,484,554
- Address
- 28, Hanjin 1-gil, Songak-eup, DANGJIN, 31720
- Web
- https://www.jw-lifescience.co.kr/
- Phone
- +82 413517600
- Auditors
- Taeil accounting corporation
Upcoming Events for 234080
Similar to 234080
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
As of Today at 21:29 UTC, shares in JW Life Science are trading at KR₩11,310. This share price information is delayed by 15 minutes.
Shares in JW Life Science last closed at KR₩11,310 and the price had moved by -7.5% over the past 365 days. In terms of relative price strength the JW Life Science share price has underperformed the FTSE Developed Asia Pacific Index by -6.44% over the past year.
The overall consensus recommendation for JW Life Science is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe JW Life Science dividend yield is 4.42% based on the trailing twelve month period.
Last year, JW Life Science paid a total dividend of KR₩500, and it currently has a trailing dividend yield of 4.42%. We do not have any data on when JW Life Science is to next pay dividends.
We do not have data on when JW Life Science is to next pay dividends. The historic dividend yield on JW Life Science shares is currently 4.42%.
To buy shares in JW Life Science you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩11,310, shares in JW Life Science had a market capitalisation of KR₩176bn.
Here are the trading details for JW Life Science:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 234080
Based on an overall assessment of its quality, value and momentum JW Life Science is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in JW Life Science is KR₩15,902. That is 40.6% above the last closing price of KR₩11,310.
Analysts covering JW Life Science currently have a consensus Earnings Per Share (EPS) forecast of KR₩1,863 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like JW Life Science. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +11.26%.
As of the last closing price of KR₩11,310, shares in JW Life Science were trading +1.19% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The JW Life Science PE ratio based on its reported earnings over the past 12 months is 6.02. The shares last closed at KR₩11,310.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
JW Life Science's management team is headed by:
- Jong Ho Lee - CHM
- Gyeong Ha Lee - CEO
- Gu Seo Park - CEO
- Seong Nam Cha - OTH
- Cheol Won Park - OTH
- Eun Gyeong Hahm - DRC
- Jae Cheol Gwon - NED
- Yin Sik Lee - NED